ArticleDrug design, development and therapy2021

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting.

Motoyasu Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.